Preferred Label : encorafenib;
UNII : 8L7891MRB6;
Origin ID : C000601108;
UMLS CUI : C4079208;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://ansm.sante.fr/tableau-atu-rtu/braftovi-75-mg-gelule
2020
false
false
false
France
French
drug information
encorafenib
encorafenib
administration, oral
Cetuximab
adult
antineoplastic combined chemotherapy protocols
BRAF V600E Mutation Present
neoplasm metastasis
colorectal neoplasms
Colorectal cancer metastatic
carbamates
sulfonamides
---
https://www.has-sante.fr/jcms/p_3225446/fr/braftovi
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
encorafenib
encorafenib
administration, oral
adult
BRAF V600E Mutation Present
colorectal neoplasms
colorectal neoplasms
mutation
neoplasm metastasis
Colorectal cancer metastatic
proto-oncogene proteins b-raf
antineoplastic combined chemotherapy protocols
Cetuximab/Encorafenib Regimen
Cetuximab
antineoplastic agents
protein kinase inhibitors
proto-oncogene proteins b-raf
metastatic colorectal cancer with a BRAF V600E mutation
evaluation of the transparency committee
carbamates
sulfonamides
---
https://www.has-sante.fr/jcms/p_3067182/fr/braftovi-mektovi
2019
false
true
false
false
France
French
antineoplastic combined chemotherapy protocols
encorafenib
binimetinib
administration, oral
protein kinase inhibitors
survival analysis
adult
insurance, health, reimbursement
melanoma
Unresectable Melanoma
BRAF V600 Mutation
proto-oncogene proteins b-raf
encorafenib
binimetinib
carbamates
sulfonamides
---
https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
encorafenib
encorafenib
drug approval
europe
treatment outcome
melanoma
melanoma
BRAF V600 Mutation
proto-oncogene proteins b-raf
mutation
antineoplastic combined chemotherapy protocols
administration, oral
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
raf kinases
protein kinase inhibitors
protein kinase inhibitors
Progression-Free survival
survival analysis
drug evaluation, preclinical
colorectal neoplasms
neoplasm metastasis
metastatic colorectal cancer with a BRAF V600E mutation
Binimetinib/Encorafenib Regimen
Cetuximab/Encorafenib Regimen
encorafenib
carbamates
sulfonamides
disease-free survival
carbamates
sulfonamides
carbamates
sulfonamides
---
